Form 4: Aspira Women's Health Director Stefanie L. Cavanaugh Reports Stock Transactions
SEC Form 4 Filing
Director Stefanie L. Cavanaugh reports the vesting and conversion of restricted stock units into common stock of Aspira Women's Health Inc.
Summary
- On September 30, 2024, Stefanie L. Cavanaugh, a director of Aspira Women's Health Inc., reported the vesting of 5,938 restricted stock units (RSUs) which converted into common stock.
- The conversion occurred at a price of $0 per share.
- Following the transaction, Cavanaugh directly owns 60,914 shares of Aspira Women's Health Inc.
- Cavanaugh also holds 17,812 unvested restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily reflect a broader industry trend. It is typical for directors and officers of publicly traded companies to receive and vest stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| 08/22/2024 | Reporting person was granted 23,750 RSUs |
| 08/26/2024 | Previous Form 4 filed with the SEC regarding the grant of RSUs. |
| 09/30/2024 | 5,938 RSUs vested and converted into common stock. |
| 10/02/2024 | Date of signature on the Form 4. |
Keywords
Form 4, Aspira Women's Health, Director, Stock Transaction, Restricted Stock Units, Common Stock, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.